FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Teva Pharmaceuticals Methylphenidate hydrochloride Recall

Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottl…

Teva Pharmaceuticals USA · Parsippany, NJ

Risk level
Class II
Reported by FDA
Feb 19, 2020
Recall ID
D-0836-2020
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Methylphenidate hydrochloride starting Jan 27, 2020. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0836-2020 on Feb 19, 2020. Reason: CGMP deviations: Product bottle may be absent of desiccant. Status: Terminated.

Why it was recalled

CGMP deviations: Product bottle may be absent of desiccant.

Product description

Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01

Lot numbers, UPCs & expiration codes

Lot #: 1332796 A, Exp 11/2020

Where it was sold

USA Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0836-2020
Classification
Class II
Status
Terminated
Recall initiated
Jan 27, 2020
FDA report date
Feb 19, 2020
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA

Original FDA data

Every field from FDA enforcement report D-0836-2020, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
84797
Address
400 Interpace Pkwy
Code information
Lot #: 1332796 A, Exp 11/2020
Postal code
07054-1120
Report date
Feb 19, 2020
Product type
Drugs
Recall number
D-0836-2020
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA
Termination date
Nov 3, 2020
Reason for recall
CGMP deviations: Product bottle may be absent of desiccant.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01
Distribution pattern
USA Nationwide
Recall initiation date
Jan 27, 2020
Initial firm notification
Letter
Center classification date
Feb 10, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0836-2020, published Feb 19, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls